Cargando…

The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator

Sacubitril/valsartan therapy reduces sudden cardiac death (SCD) among patients with reduced ejection fraction (HFrEF) when compared to guidelines recommended doses of enalapril, however the mechanism is still not clear. There are few, contrasting results about the effect of sacubitril/valsartan on a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Vincenzo, Bottino, Roberta, Rago, Anna, Papa, Andrea Antonio, Liccardo, Biagio, Proietti, Riccardo, Manna, Vincenzo, Golino, Paolo, D’Onofrio, Antonio, Nigro, Gerardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230317/ https://www.ncbi.nlm.nih.gov/pubmed/32294983 http://dx.doi.org/10.3390/jcm9041111

Ejemplares similares

Use of Sacubitril/Valsartan Prior to Primary Prevention Implantable Cardioverter Defibrillator Implantation
por: Ozier, Daniel, et al.
Publicado: (2022)

Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients
por: Russo, Vincenzo, et al.
Publicado: (2022)

Inappropriate shocks due to air entrapment in patients with subcutaneous implantable cardioverter‐defibrillator: A meta‐summary of case reports
por: Iavarone, Michele, et al.
Publicado: (2022)

Device-Related Complications and Inappropriate Therapies Among Subcutaneous vs. Transvenous Implantable Defibrillator Recipients: Insight Monaldi Rhythm Registry
por: Russo, Vincenzo, et al.
Publicado: (2022)

Effects of COVID‐19 lockdown on arrhythmias in patients with implantable cardioverter‐defibrillators in southern Italy
por: Ducceschi, Valentino, et al.
Publicado: (2022)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
por: Medeiros, Paulo, et al.
Publicado: (2023)

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report
por: Corrado, Egle, et al.
Publicado: (2020)

Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF
por: Felker, G. Michael, et al.
Publicado: (2021)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Beneficial effects of one-month sacubitril/valsartan treatment in a patient affected by end-stage dystrophinopathic cardiomyopathy
por: Papa, Andrea Antonio, et al.
Publicado: (2020)

Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
por: Russo, Vincenzo, et al.
Publicado: (2019)

COVID-19 and Heart: From Clinical Features to Pharmacological Implications
por: Russo, Vincenzo, et al.
Publicado: (2020)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study
por: D’Onofrio, Antonio, et al.
Publicado: (2018)

Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
por: Russo, Vincenzo, et al.
Publicado: (2020)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
por: Rago, Anna, et al.
Publicado: (2023)

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology
por: Canale, Maria Laura, et al.
Publicado: (2022)

Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis
por: Nuechterlein, Kaitlin, et al.
Publicado: (2021)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences
por: Castrichini, Matteo, et al.
Publicado: (2020)

Evolution of extravascular implantable cardioverter-defibrillator therapy for ventricular arrhythmias
por: Römers, Hans, et al.
Publicado: (2022)

Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients
por: El-Battrawy, Ibrahim, et al.
Publicado: (2019)

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach
por: Zhou, Yu, et al.
Publicado: (2022)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
por: Cacciatore, Francesco, et al.
Publicado: (2020)

Echocardiographic Features of Cardiac Involvement in Myotonic Dystrophy 1: Prevalence and Prognostic Value
por: Russo, Vincenzo, et al.
Publicado: (2023)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rbukrd5tutd08rqgvfopqueuqh